Astrazeneca plc - ADR
AZN
Market Cap$216.78B
Close$
Earnings Call Q4 2024
February 6, 2025 - AI Summary
Strong Financial Performance: AstraZeneca reported a 21% increase in total revenue for 2024, driven by significant demand for its medicines. Core EPS grew by 19%, highlighting a robust underlying business momentum. The company exceeded its guidance for revenue growth, fueled by strong product sales and collaborations.
Key Pipeline Advancements: AstraZeneca achieved notable progress in its pipeline with nine pivotal trial readouts in 2024, anticipated to generate over $5 billion in peak year revenue. The company has set an ambitious goal of delivering 20 new medicines by 2030, with eight already approved, including the recent launch of Datroway.
Emerging Market Opportunities: The company experienced a 22% growth rate in emerging markets in 2024 and anticipates sustained demand in regions like China, despite recent headwinds from regulatory challenges. The significant unmet medical need and increased investment in healthcare present long-term growth opportunities.
Exclusive for Stockcircle Pro members
Sign up
$200.73
195.8% upside
Current Fair Value
195.8% upsideUndervalued by 195.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $216.78 Billion |
|---|---|
| Enterprise Value | $242.81 Billion |
| Dividend Yield | $1.54 (1.91338917423943%) |
| Earnings per Share | $4.53 |
| Beta | 0.25 |
| Outstanding Shares | 3,100,000,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 29.66 |
|---|---|
| PEG | 52.74 |
| Price to Sales | 3.99 |
| Price to Book Ratio | 5.22 |
| Enterprise Value to Revenue | 4.49 |
| Enterprise Value to EBIT | 23.22 |
| Enterprise Value to Net Income | 34 |
| Total Debt to Enterprise | 0.13 |
| Debt to Equity | 0.77 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About AstraZeneca Plc
CEO: Pascal Soriot AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respira...